Journal of Cellular and Molecular Medicine · 2017 · 32 citations · 39 references
Life SciencesCancer BiologyMolecular BiologyCancer GeneticsGene ExpressionMolecular OncologyEpigenetic Alterations In CancerEpigenetic Regulation In CancerMalignant NeoplasmsTumor Suppressor Gene InactivationTumor Suppressor GenesAberrant Dna MethylationBreast Cancer EpigeneticsBreast Cancer ProgressionPromoter Cpg MethylationPromoter HypermethylationPromoter MethylationPromoter Methylation AnalysisTumor Suppressor Gene Hypermethylation
Chromosome region 3p12-14 is an important tumour suppressor gene (TSG) locus for multiple cancers. ADAMTS9, a member of the metalloprotease large family, has been identified as a candidate 3p14.2 TSG inactivated by aberrant promoter CpG methylation in several carcinomas, but little known about its expression and function in breast cancer. In this report, ADAMTS9 expression and methylation was analysed in breast cancer cell lines and tissue samples. ADAMTS9 RNA was significantly down-regulated in breast cancer cell lines (6/8). After treating the cells with demethylation agent Aza and TSA, ADAMTS9 expression was dramatically increased. Bisulphite genomic sequencing and methylation-specific PCR detected promoter methylation, which was associated with decreased ADAMTS9 expression. Hypermethylation was also detected in 130/219 (59.4%) of primary tumours but only in 4.5% (2/44) of paired surgical margin tissues. Ectopic expression of ADAMTS9 in tumor cells induced significant growth suppression, cell cycle arrest at the G0/G1 phase, enhanced apoptosis and reduced cell migration and invasion. Conditioned culture medium from ADAMTS9-transfected BT549 cells markedly disrupted tube formation ability of human umbilical vein endothelial cell (HUVEC) in Matrigel. Furthermore, ADAMTS9 inhibited AKT signaling and its downstream targets (MDM2, p53, p21, p27, E-cadherin, VIM, SNAIL, VEGFA, NFκB-p65 and MMP2). In addition, we demonstrated, for the first time, that ADAMTS9 inhibits AKT signaling, through suppressing its upstream activators EGFR and TGFβ1/TβR(I/II) in breast cancer cells. Our results suggest that ADAMTS9 is a TSG epigenetically inactivated in breast cancer, which functions through blocking EGFR- and TGFβ1/TβR(I/II)-activated AKT signaling.
39
Cancer statistics in China, 2015
Wanqing Chen, Rongshou Zheng, Peter D. Baade et al. · CA A Cancer Journal for Clinicians · 2016 · 18K citations · Full text
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2016 · 16.2K citations · Full text
Bert Vogelstein, David P. Lane, Arnold J. Levine · Nature · 2000 · 6.6K citations
PI3K/AKT/mTOR Pathway in Angiogenesis
Jayashree Karar, Amit Maity · Frontiers in Molecular Neuroscience · 2011 · 1.5K citations · Full text